Evidence map›Paper›PMID 29496470›Full record

ArticleThe Journal of urology2018

Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging.

Mahyar Kashan, Mazyar Ghanaat, Andreas M Hötker, Cihan Duzgol, Alejandro Sanchez, Renzo G DiNatale, Kyle A Blum, Maria F Becerra, Brandon J Manley, Jozefina Casuscelli and 6 more

Abstract read
In one paragraph

Article in The Journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Article
  6. Review
  7. [Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Update on MRI of Cystic Renal Masses Including Bosniak Version 2019.Journal of magnetic resonance imaging : JMRI · 2021
    Review
  14. Imaging Characterization of Renal Masses.Medicina (Kaunas, Lithuania) · 2021
    Review
  15. Review
  16. A Festschrift in Honor of Edward M. Messing, MD, FACS.Bladder cancer (Amsterdam, Netherlands) · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Mahyar KashanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Mazyar GhanaatUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Andreas M HötkerDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Cihan DuzgolDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Alejandro SanchezUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Renzo G DiNataleUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Kyle A BlumUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Maria F BecerraUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Urology, Miller School of Medicine, University of Miami, Miami, Florida.
Brandon J ManleyUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Jozefina CasuscelliDepartment of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Urology, Ludwig-Maximilians University, Munich, Germany.
Michael ChiokUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Satish K TickooDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Oguz AkinDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: hakimia@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
UROLOGY ONCOLOGY RESEARCH TRAINING GRANTT32CA082088 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Brett Stewart Carver · 1999 to 2026
$7.1M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA082088
6 · The paper itself

Abstract

purposeWe evaluated the outcomes of surgical intervention and active surveillance in patients diagnosed with cystic renal cell carcinoma at our hypothesized radiological cutoff of greater than 50% cystic. MATERIALS AND

methodsWe identified all 430 patients with a pathologically confirmed cystic renal mass that fit our criteria from 2000 to 2015. The 292 patients with a lack of computerized tomography, tumors less than 50% cystic on imaging, multifocal tumors and prior renal cell carcinoma were excluded from study. Patients were stratified into benign or malignant subgroups, and radiological, clinicopathological and oncologic features were determined. Univariate and multivariate associations between clinicoradiological parameters in each group were analyzed. We similarly reviewed the records of a separate cohort of patients treated with active surveillance for cystic renal cell carcinoma.

resultsOf the 138 identified cases of cystic renal cell carcinoma 102 (73.9%) were renal cell carcinoma and 36 (26.1%) were benign masses. Of the tumors 77.5% were Fuhrman grade 1-2, 83.4% were stage pT2 or less and 65.9% showed clear cell histology. On univariate analysis male gender, a solid component and increasing Bosniak classification were significant for malignancy. In a separate cohort we identified 38 patients on active surveillance. The growth rate was 1.0 mm per year overall and 2.3 mm per year for the solid component. At a median followup of more than 4 years in all cohorts there was no evidence of recurrence or metastasis of cystic renal cell carcinoma.

conclusionsPatients with unifocal cystic renal cell carcinoma evaluated using a standardized radiological threshold of greater than 50% cystic had an excellent prognosis on active surveillance and after surgical resection.

Indexed as

NephrectomyWatchful WaitingCarcinoma, Renal CellFemaleFollow-Up StudiesHumansKidneyKidney Diseases, CysticKidney NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesTomography, X-Ray ComputedTreatment Outcomecarcinomacystskidneynephrectomyrenal cellwatchful waiting

Identifiers

PMID29496470
PMCPMC6050111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.